Last reviewed · How we verify
Multi-center, Open Label, 18-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HT (ACADEMY)
This study assessed the efficacy and safety of combination therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in patients with stage II Hypertension.
Details
| Lead sponsor | Novartis |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 230 |
| Start date | 2010-01 |
| Completion | 2010-10 |
Conditions
- Stage II Hypertension
Interventions
- Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)
Primary outcomes
- Percentage of participants with stage II hypertension achieving blood pressure (BP) goal — 18 weeks
The BP goal for non-diabetic patient is defined as msSBP \< 140 mmHg and msDBP \< 90 mmHg. The BP goal for diabetic patient is msSBP \< 130 mmHg and msDBP \< 80 mmHg) in patients with stage II hypertension.
Countries
Thailand